196 related articles for article (PubMed ID: 29979390)
1. High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Marinelli A; Lamberti G; Cerbone L; Cordua N; Buonerba C; Peluso G; Di Lorenzo G; De Placido S
Medicine (Baltimore); 2018 Jul; 97(27):e11254. PubMed ID: 29979390
[TBL] [Abstract][Full Text] [Related]
2. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
[TBL] [Abstract][Full Text] [Related]
4. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.
Addeo R; Lamberti G; Simonetti G; Iodice P; Marinelli A; Montella L; Cappabianca S; Gaviani P; Caraglia M; Prete SD; Silvani A
CNS Oncol; 2019 Jun; 8(2):CNS32. PubMed ID: 31290692
[No Abstract] [Full Text] [Related]
5. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V
J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
[TBL] [Abstract][Full Text] [Related]
8. Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Santoni M; Paccapelo A; Burattini L; Onofri A; Cascinu S
Anticancer Res; 2012 Mar; 32(3):1099-101. PubMed ID: 22399639
[TBL] [Abstract][Full Text] [Related]
9. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and daily temozolomide for recurrent glioblastoma.
Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
[TBL] [Abstract][Full Text] [Related]
11. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
[TBL] [Abstract][Full Text] [Related]
12. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Fazeny-Dörner B; Veitl M; Wenzel C; Piribauer M; Rössler K; Dieckmann K; Ungersböck K; Marosi C
Anticancer Drugs; 2003 Jul; 14(6):437-42. PubMed ID: 12853885
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Prados MD; Yung WK; Fine HA; Greenberg HS; Junck L; Chang SM; Nicholas MK; Robins HI; Mehta MP; Fink KL; Jaeckle KA; Kuhn J; Hess KR; Schold SC;
Neuro Oncol; 2004 Jan; 6(1):33-7. PubMed ID: 14769138
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
18. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
19. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
Gallo C; Buonerba C; Di Lorenzo G; Romeo V; De Placido S; Marinelli A
J Neurooncol; 2010 Nov; 100(2):311-9. PubMed ID: 20556481
[TBL] [Abstract][Full Text] [Related]
20. Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Balducci M; Chiesa S; Diletto B; D'Agostino GR; Mangiola A; Manfrida S; Mantini G; Albanese A; Fiorentino A; Frascino V; De Bari B; Micciche' F; De Rose F; Morganti AG; Anile C; Valentini V
Neuro Oncol; 2012 Jan; 14(1):79-86. PubMed ID: 21993440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]